Michael H. Tardugno's career has been exclusively focused in healthcare with 30 years of experience in the pharmaceutical and medical device industries. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations. Mr. Tardugno holds a BS from St. Bonaventure University and attended the Harvard Business School executive program.
 

Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Scientific Officer, EGEN, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Scientific Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a PhD in Physiology/Pharmacology from Ohio University and received postdoctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of nonviral gene therapy. He has authored more than 40 publications in the area of nonviral gene therapy, resulting from his active career in research and development. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.

Jeffrey W. Church was appointed Senior Vice President, Corporate Strategy and Investor Relations on July 8, 2011. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. Mr. Church brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining the Company, Mr. Church held senior financial executive positions with several private and public clinical stage Life Science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm, Price Waterhouse. Mr. Church holds a BS degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.